uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease

Loading news article.

uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease | WAPE

uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease

Article summary

Related companies

Comments —